# Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

> **NCT06573398** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Carcinoma, Pancreatic Ductal

## Interventions

- **COMBINATION_PRODUCT:** SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin

## Key facts

- **NCT ID:** NCT06573398
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573398, "Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06573398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*